

Special Issue

Novel Therapeutic Approaches for Neurodegenerative Diseases Treatment

Message from the Guest Editors

Neurodegenerative disorders are typically characterized by the progressive loss of specific populations of neurons in the brain. Despite recent advances in the field, most of the molecular mechanisms involved in disease progression are not completely understood.

However, since protein aggregation is a central event in neurological disorders, a variety of novel approaches are focused on developing novel pharmacologically active molecules targeting this process. Without doubt, such ground-breaking discoveries will facilitate the structure-based design of novel functional and specific protein aggregation inhibitors. Additionally, we focus on nanomaterials targeting neurodegenerative disorders as efficient drug delivery systems. The focus of this Special Issue is on the development and identification of novel molecules and therapeutic approaches dedicated to treat neurodegenerative diseases. The topics include but are not limited to: the design and development of novel protein-aggregation inhibitors; drug delivery using nanotechnology; and the development and characterization of pharmacologically active compounds targeting proteostasis and neurodegeneration

Guest Editors

Dr. Javier Garcia-Pardo

Institut de Biotecnologia i de Biomedicina (IBB), Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain

Prof. Dr. Salvador Ventura

1. Institute of Biotechnology and Biomedicine, Autonomous University of Barcelona, 08193 Bellaterra, Spain
2. Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona, 08193 Bellaterra, Spain

Deadline for manuscript submissions

closed (31 January 2023)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 12.5
Indexed in PubMed



mdpi.com/si/110652

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 12.5
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.7 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2025).